Solexa May Not Recognize Revenue From First Sales Until Q4; Revs Delayed Once Already | GenomeWeb
NEW YORK (GenomeWeb News) - Solexa said last week it may not recognize revenues from its first instrument sales to two early-access customers until the end of the year because it still has not met certain pre-agreed product specifications.
 
The company had originally planned to book receipts from early-access sales in the second quarter but in May pushed back that timeline to the third quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.